Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658671 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
A Phase 1 study of Advanced Cancer, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 2
- Study locations
NCT00658671: Completed Phase 1 study of Advanced Cancer, sponsored by CASI pharmaceuticals.
NCT00658671 is a Phase 1 study of Advanced Cancer that has completed, run by CASI pharmaceuticals. The registered enrollment target is 67 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00658671, a Phase 1 study of Advanced Cancer, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 2
- Study locations
Study Summary
A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.
Conditions Studied
Interventions
- DRUG ENMD-2076
Study Locations (2)
Colorado
- University of Colorado Hospital - Aurora
Massachusetts
- Dana Farber/Harvard Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
What the finished NCT00658671 record still lists
NCT00658671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which ENMD-2076 is the first listed.
NCT00658671 reports a single indexed study location in Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00658671 about?
NCT00658671 is a clinical study titled "A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer". A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.
What is the current status of trial NCT00658671?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2008-04. Estimated completion is 2012-06.
What conditions does trial NCT00658671 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00658671?
The interventions under investigation include: ENMD-2076 (DRUG).
Who is sponsoring clinical trial NCT00658671?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00658671 being conducted?
This trial has 2 study locations across Colorado, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00658671's enrollment target sits among peer trials
67 74th of 122 higher than 49 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia